These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 29315113)

  • 21. Pharmacokinetic and pharmacodynamic evaluation of raltegravir and experience from clinical trials in HIV-positive patients.
    Calcagno A; D'Avolio A; Bonora S
    Expert Opin Drug Metab Toxicol; 2015 Jul; 11(7):1167-76. PubMed ID: 26073580
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The HIV-1 integrase genotype strongly predicts raltegravir susceptibility but not viral fitness of primary virus isolates.
    Buzón MJ; Dalmau J; Puertas MC; Puig J; Clotet B; Martinez-Picado J
    AIDS; 2010 Jan; 24(1):17-25. PubMed ID: 19770695
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Resistance to HIV-1 integrase inhibitors: A structural perspective.
    Mouscadet JF; Delelis O; Marcelin AG; Tchertanov L
    Drug Resist Updat; 2010; 13(4-5):139-50. PubMed ID: 20570551
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ultradeep sequencing detection of the R263K integrase inhibitor drug resistance mutation.
    Jaffré J; Armenia D; Bellocchi MC; Wirden M; Carioti L; Lambert S; Valantin MA; Nguyen T; Simon A; Katlama C; Andreoni M; Perno CF; Calvez V; Ceccherini-Silberstein F; Marcelin AG; Todesco E
    J Antimicrob Chemother; 2017 May; 72(5):1537-1539. PubMed ID: 28088769
    [No Abstract]   [Full Text] [Related]  

  • 25. Lack of HIV-1 integrase inhibitor resistance among 392 antiretroviral-naïve individuals in a tertiary care hospital in Beijing, China.
    Liu L; Dai L; Yao J; Pan P; Li L; Liu Z; An X; Sun L; Wu H; Su B; Zhang T
    AIDS; 2019 Oct; 33(12):1945-1947. PubMed ID: 31491787
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Brief Report: T-Cell Receptor α Repertoire Diversity at Birth After in utero Exposure to HIV Integrase Strand-Transfer Inhibitors.
    de Villartay JP; Pannier E; Sibiude J; Frange P; Tubiana R; Blanche S
    J Acquir Immune Defic Syndr; 2023 Mar; 92(3):260-262. PubMed ID: 36343360
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [HIV-1 integrase inhibitor resistance among treatment naïve patients in Gran Canaria, 2017].
    Pena López MJ; Hernández Febles M; Medina Galindo JA; Pérez Jiménez RD
    Rev Esp Quimioter; 2018 Oct; 31(5):459-460. PubMed ID: 30221902
    [No Abstract]   [Full Text] [Related]  

  • 28. Evolution of a novel pathway leading to dolutegravir resistance in a patient harbouring N155H and multiclass drug resistance.
    Hardy I; Brenner B; Quashie P; Thomas R; Petropoulos C; Huang W; Moisi D; Wainberg MA; Roger M
    J Antimicrob Chemother; 2015 Feb; 70(2):405-11. PubMed ID: 25281399
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel integrase inhibitors for HIV.
    Prada N; Markowitz M
    Expert Opin Investig Drugs; 2010 Sep; 19(9):1087-98. PubMed ID: 20707594
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting the HIV integration process in antiviral therapy.
    McNeely M; Christ F; Thys W; Debyser Z
    J HIV Ther; 2008 Dec; 13(4):83-92. PubMed ID: 19418658
    [No Abstract]   [Full Text] [Related]  

  • 31. Prevalence of HIV-1 integrase mutations related to resistance to dolutegravir in raltegravir naïve and pretreated patients.
    Saladini F; Meini G; Bianco C; Monno L; Punzi G; Pecorari M; Borghi V; Di Pietro M; Filice G; Gismondo MR; Micheli V; Penco G; Carli T; De Luca A; Zazzi M;
    Clin Microbiol Infect; 2012 Oct; 18(10):E428-30. PubMed ID: 22716970
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evolution patterns of raltegravir-resistant mutations after integrase inhibitor interruption.
    Canducci F; Barda B; Ceresola E; Spagnuolo V; Sampaolo M; Boeri E; Nozza S; Cossarin F; Galli A; Gianotti N; Castagna A; Lazzarin A; Clementi M
    Clin Microbiol Infect; 2011 Jun; 17(6):928-34. PubMed ID: 20854427
    [TBL] [Abstract][Full Text] [Related]  

  • 33. No residual activity of raltegravir after development of 148 complex mutations in vivo.
    Khanlou H; Sayana S; Acosta E
    J Int Assoc Physicians AIDS Care (Chic); 2008; 7(6):281-2. PubMed ID: 19164138
    [No Abstract]   [Full Text] [Related]  

  • 34. Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to first-generation integrase inhibitors, but minor fold changes to inhibitors with second-generation resistance profiles.
    Goethals O; Vos A; Van Ginderen M; Geluykens P; Smits V; Schols D; Hertogs K; Clayton R
    Virology; 2010 Jul; 402(2):338-46. PubMed ID: 20421122
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Integrase variability and susceptibility to HIV integrase inhibitors: impact of subtypes, antiretroviral experience and duration of HIV infection.
    Garrido C; Geretti AM; Zahonero N; Booth C; Strang A; Soriano V; De Mendoza C
    J Antimicrob Chemother; 2010 Feb; 65(2):320-6. PubMed ID: 20007331
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterization and structural analysis of HIV-1 integrase conservation.
    Ceccherini-Silberstein F; Malet I; D'Arrigo R; Antinori A; Marcelin AG; Perno CF
    AIDS Rev; 2009; 11(1):17-29. PubMed ID: 19290031
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Performance of the Abbott RealTime HIV-1 viral load assay is not impacted by integrase inhibitor resistance-associated mutations.
    Young TP; Cloherty G; Fransen S; Napolitano L; Swanson P; Herman C; Parkin NT; Hackett J
    J Clin Microbiol; 2011 Apr; 49(4):1631-4. PubMed ID: 21289145
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dynamics of raltegravir resistance profile in an HIV type 2-infected patient.
    Xu L; Anderson J; Garrett N; Ferns B; Wildfire A; Cook P; Workman J; Graham S; Smit E
    AIDS Res Hum Retroviruses; 2009 Aug; 25(8):843-7. PubMed ID: 19618998
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The S230R Integrase Substitution Associated With Virus Load Rebound During Dolutegravir Monotherapy Confers Low-Level Resistance to Integrase Strand-Transfer Inhibitors.
    Pham HT; Labrie L; Wijting IEA; Hassounah S; Lok KY; Portna I; Goring ME; Han Y; Lungu C; van der Ende ME; Brenner BG; Boucher CA; Rijnders BJA; van Kampen JJA; Mesplède T; Wainberg MA
    J Infect Dis; 2018 Jul; 218(5):698-706. PubMed ID: 29617824
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Short Communication: Dolutegravir-Based Regimens Are Active in Integrase Strand Transfer Inhibitor-Naive Patients with Nucleoside Reverse Transcriptase Inhibitor Resistance.
    Demarest J; Underwood M; St Clair M; Dorey D; Brown D; Zolopa A
    AIDS Res Hum Retroviruses; 2018 Apr; 34(4):343-346. PubMed ID: 29444582
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.